Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis.
Small-cap stocks are surging ahead of the expected interest rate cut by the Federal Reserve, outperforming their larger-cap counterparts. However, potential for gains may be hindered by sluggish earnings and uncertain economic outlook.
Applied Therapeutics stock rises as the FDA no longer requires an Advisory Committee meeting, keeping the Priority Review on track, with the PDUFA target date set for November 28.
William Blair has initiated coverage on Applied Therapeutics highlighting its focus on rare diseases such as galactosemia, SORD deficiency, and diabetic cardiomyopathy. With govorestat (AT-007) poised for a potential 2025 launch, analysts predict strong market performance and significant sales growth.
FDA extends the review period for Applied Therapeutics' NDA for govorestat, targeting Classic Galactosemia treatment. The new action date is set for November 28, 2024. Applied Therapeutics anticipates a decision from EMA in Q4 2024.
Shares of Doma Holdings Inc. (NYSE: DOMA) rose sharply in today’s pre-market trading after the company entered a merger transaction with TRG to go private at $6.29 per share in cash. Doma Holdings shares jumped 34.1% to $6.09 in pre-market trading
